| Cat.No. | Name | Information |
|---|---|---|
| M6151 | Larotrectinib (LOXO-101) | Larotrectinib (LOXO-101) is a potent, ATP competitive TRK inhibitor with IC50s in low nanomolar range for inhibition of all TRK family members in binding and cellular assays, with 100x selectivity over other kinases, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
| M14580 | Cyclotraxin B acetate | Cyclotraxin B acetate, a cyclic peptide, is a highly potent and selective TrkB inhibitor without altering the binding of BDNF. |
| M14579 | AZ-23 | AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively. |
| M11011 | LM22B-10 | LM22B-10 is a TrkB/TrkC neurotrophic factor receptor activator that induces activation of TrkB, TrkC, AKT and ERK in vitro. |
| M10936 | Taletrectinib | Taletrectinib (DS-6051b) is a potent orally active next-generation selective ROS1/NTRK inhibitor. Taletrectinib is 0.207, 0.622, 2.28, and 0.98 nM, respectively IC50 It has a strong inhibitory effect on recombinant ROS1, NTRK1, NTRK2 and NTRK3. Taletrectinib also inhibits ROS1 G2032R and other ANTI-Crizotinib ROS1 mutants. |
| M10736 | CH7057288 | CH7057288 is a potent selective TRK inhibitor. |
| M9107 | Selitrectinib (LOXO-195) | Selitrectinib (LOXO-195) is a potent and selective, next-generation TRK inhibitor, with IC50 values of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC, respectively. |
| M6910 | LM22A-4 | LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research. |
| M6211 | LOXO-101 sulfate | LOXO-101 sulfate is an oral potent and selective ATP-competitive inhibitor of tropomyosin receptor kinases (TRK). |
| M5304 | 7,8-Dihydroxyflavone | 7,8-Dihydroxyflavone acts as a potent and selective small-molecule agonist of the TrkB receptor (Kd ≈ 320 nM), the main signaling receptor of brain-derived neurotrophic factor (BDNF). |
| M5074 | ANA-12 | ANA-12 is a selective TrkB antagonist with Kd of 10 nM and 12 μM for the high and low affinity sites, respectively. |
| M2744 | GW441756 | GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2. |
| M2585 | GNF-5837 | GNF-5837 is a potent pan-Trk inhibitor which display antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively. |
| M43539 | Protein kinase inhibitor 4 | Protein kinase inhibitor 4 is a protein kinase inhibitor that inhibits TRK-A and ROS1 (IC50=3.0 nM and 104 nM respectively). |
| M42719 | TRK-IN-22 | TRK-IN-22 is a TRK inhibitor. |
| M42718 | TrkB-IN-1 | TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. |
| M42717 | Type II TRK inhibitor 1 | Type II TRK inhibitor 1 is a potent TRK inhibitor, which inhibits various TRK fusion protein variants and wild type. |
| M42716 | TRK-IN-23 | TRK-IN-23 is a potent and orally active TRK inhibitor with IC50 values of 0.5 nM, 9 nM, 14 nM, 4.4 nM, and 4.8 nM against TRKA, TRKC, TRKAG595R, TRKAF589L, and TRKAG667C, respectively. |
| M28931 | Anizatrectinib | Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al. |
| M24972 | Bedinvetmab | Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
